ADVANCES IN THE CELL-BASED TREATMENT OF NEONATAL HYPOXIC-ISCHEMIC BRAIN INJURY

Mibel M. Pabon and Cesar V. Borlongan
Department of Neurosurgery and Brain Repair, University of South Florida, College of Medicine, Tampa, Florida 33612 USA

Abstract

Stem cell therapy for adult stroke has reached limited clinical trials. Here, we provide translational research guidance on stem cell therapy for neonatal hypoxic-ischemic brain injury requiring a careful consideration of clinically relevant animal models, feasible stem cell sources, and validated safety and efficacy endpoint assays, as well as a general understanding of modes of action of this cellular therapy. To this end, we refer to existing translational guidelines, in particular the recommendations outlined in the consortium of academicians, industry partners and regulators called Stem cell Therapeutics as an Emerging Paradigm for Stroke or STEPS. Although the STEPS guidelines are directed at enhancing the successful outcome of cell therapy in adult stroke, we highlight overlapping pathologies between adult stroke and neonatal hypoxic-ischemic brain injury. We are, however, cognizant that the neonatal hypoxic-ischemic brain injury displays disease symptoms distinct from adult stroke in need of an innovative translational approach that facilitates the entry of cell therapy in the clinic. Finally, insights into combination therapy are provided with the vision that stem cell therapy may benefit from available treatments, such as hypothermia, already being tested in children diagnosed with hypoxic-ischemic brain injury.

Keywords
cerebral palsy; stem cells; hypothermia; neurorestoration; translational; consortium; combination therapy

Neonatal Hypoxic-Ischemic Brain Injury: A Disease Target for Cell Therapy

Neonatal hypoxic-ischemic brain injury is the major cause of hypoxic-ischemic encephalopathy (HIE), cerebral palsy (CP), and periventricular leukomalacia (PVL). Children diagnosed with hypoxic-ischemic brain injury present with neurodevelopmental deficits such as learning disabilities, mental retardation, and hearing and visual impairments. HIE is the brain manifestation of systemic asphyxia [1], afflicting 1.5 of 1,000 full-term live birth infants [2–4]. In this paper, the term HIE and the alternative term of neonatal encephalopathy (NE) [5, 6] are used interchangeably. A discussion on these two terminologies has been a topic for debate [7, 8]. Despite a concerted effort among researchers and clinicians to employ sensitive diagnostic tools, encephalopathy has not been diagnosed in premature infants compared to full term infants [9–11]. Mortality in newborns with HIE is as high as 50% [12], and 25% of those survivors display CP symptoms permanently [13, 14]. Ischemic perinatal stroke accounts for 30% of children with CP [15]. PVL, a cerebral white matter injury, is seen in 50% of neonates with extremely low birth
weights with 90% of survivors exhibiting CP symptoms [16]; however, ultrasonography studies report lower than 50% incidence of PVL [17–19]. Because of overlapping pathophysiological symptoms between neonatal hypoxic-ischemic brain injury and adult stroke, novel treatments such as cell-based therapies, which are being tested in stroke, may prove effective in neonatal hypoxic-ischemic brain injury. Understanding the neurochemical cascade of events is critical for initiating treatment intervention in neonates [20]. In particular, therapeutic benefits may be achieved by abrogating the “secondary energy failure” or “excito-oxidative cascade” [20, 21], which is characterized by increased excitation of NMDA receptors coupled with aberrant oxidative stress due to mitochondrial dysfunction, altogether depleting energy from the brain seen in babies with hypoxic-ischemic injury [20]. The present treatment for HIE is hypothermia [22–24], which is largely effective in newborns with a gestational age of ≥36 weeks [24, 25] diagnosed with moderate to severe HIE [23, 24], but neurodevelopmental deficits persist in 40–50% of patients even after hypothermia [24]. Combination therapy of cell transplantation and hypothermia may benefit neonates with moderate to severe HIE (Figure 1).

Translating Stem Cells from Bench to Bedside

Stem cell Therapeutics as an Emerging Paradigm for Stroke (STEPS) is a consortium of academicians, industry partners and regulators, including the National Institutes of Health (NIH) and the U.S. Food and Drug Administration (FDA) have regularly convened to enhance the successful outcome of cell therapy in stroke patients [26–33]. The establishment of a Baby STEPS consortium should allow a safe and effective translation of cell therapy in neonatal hypoxic-ischemic brain injury. We enumerate below critical gating criteria in designing translational studies in order to aid in the formulation of Baby STEPS guidelines.

Experimental Models of Neonatal Hypoxic-Ischemic Brain Injury

Vannucci’s rodent model of neonatal hypoxic-ischemic brain injury resembles many human neonate HIE pathological events [34]. Using 7-day old postnatal rats, which underwent ligation of unilateral carotid artery combined with systemic hypoxia generated cell death to cerebral cortex, subcortical and periventricular white matter, striatum, and hippocampus ipsilateral to the ligated artery [35]. Mice have also been used to create the Vannucci model [36] with varying pathological outcomes depending on the mouse strain [37–40]. Animal species and strain should be considered in HIE modeling.

Equally an important variable to control in experimental HIE is the age of the animals. Young animals tend to be resistant against hypoxia; indeed, 1–2 day old postnatal rats need to be exposed to more severe hypoxia than 7-day old postnatal rats to achieve successful HIE symptoms. However, the younger animals display worse white matter injury than the older rats [36]. Age as a key factor in HIE modeling is further evidenced by a focal subcortical cell loss accompanied by a surge in proliferating oligodendrocyte progenitor cells following HIE in young neonates, but rather modest in older animals [41–45]. Such age-related neurodegeneration and neuroregeneration after HIE requires standardization of animals models in order to better assess the therapeutic effects of experimental treatments.

Another factor to consider in animal models of HIE is gender. Neonatal female rats exhibit much more reduction in infarct volume and better improvement in sensorimotor task after perinatal hypoxic-ischemic brain injury and treatment with erythropoietin compared to male rats exposed to the same treatment conditions [46]. Other laboratory studies have observed gender influence in similar injury models [47, 48], altogether suggesting the need to monitor the gender of animals in experimental HIE.
The approximation of the clinical pathology of HIE is an imperative goal in standardizing the animal models. A species mimicking the human condition should allow better evaluation of experimental treatments for HIE. Among the species employed as closely resembling humans include fetal and neonatal nonhuman primate, sheep, lamb, puppy, piglet, and rabbit [34, 49–54]. The expensive cost of using large animals, however, has hindered access to these clinically relevant experimental models. The piglet model resembles closely the weight and the size of a newborn infant, thus a good platform for translational research of treatment interventions for neonates [55, 56]. Using this piglet model, phosphorylated metabolites were shown to be temperature-sensitive and that the more severe the energy depletion the worse the secondary energy failure, exacerbating neuronal death [55, 56]. These findings implicate the need for therapeutic strategies that can regulate temperature and maintain brain energy.

Assessment of pathological improvements after therapy in experimental models needs to consider developing tests for short and long-term functional outcomes that are species specific that closely approximate the human condition. However, while experimental models of brain injury allow the investigators to control the nature, severity, and timing of injury in relation to origin and progression of pathology, and treatment intervention, characterizing the phenotype of encephalopathy in neonates has been a major challenge. Indeed, this disconnect between the experimental models and the clinical setting has remained a key barrier in implementing “timely” interventions in babies with neonatal encephalopathy, which is in stark contrast to situations in adults with traumatic encephalopathy, or strokes. Recognizing this translational research gap is critical when contemplating with designing therapeutic intervention studies for clinical applications in neonates.

**Characterizing Transplantable Stem Cells**

A well-defined phenotypic characterization of stem cells is necessary to gain a better understanding of basic stem cell biology and translational potential [57–60]. The identity of the stem cells for transplantation in HIE is critical to validate the cell population that is safe and effective, but also to allow insights into the mechanism of action mediating the functional recovery after transplantation (discussed in detail below). Whereas the original concept of cell transplantation in brain injury is to replace damaged neurons, the recognition of neurodegeneration in multiple cell types has reinvented brain repair not as a single neuronal cell replacement therapy, but as a multi-pronged restorative mechanism. These reparative events involve both exogenous and endogenous neurons, glial cells, endothelial cells, among many other cell types, synergistically acting in tandem with the grafted stem cells’ bystander effects, such as: trophic, neurogenic, vasculogenic, angiogenic, and synaptogenic properties [61]. Defining the stem cell source is also important for validation and replication of laboratory studies. As we envision the clinical product, the availability of thaw-and-inject transplantable stem cells has a practical application in the clinical setting. A readily available cryopreservable stem cell product, which can be shipped frozen and thawed at the clinic for transplantation, will be preferred for neonatal diseases. Additionally, the use of autologous stem cells, including those harvested from craniofacial neural crest or from fibroblasts for generating induced pluripotent stem cells, is attractive because they circumvent graft rejection and its adverse side effects. A small pilot study shows that intravenous injection of autologous cord blood is safe in CP children [62]. Another study suggests that placental tissue obtained during prenatal chorionic villous sampling or at delivery can be a good source of autologous stem cells which can be grafted during the last month of gestation or the first few months after delivery if neurodegeneration is detected in the baby [63].
Safety and Efficacy Endpoints of Cell Therapy

Routine functional assays of safety and efficacy of experimental treatments in HIE include behavioral tests that can assess motor and cognitive improvements and histological assays, such as markers of decreased cell loss/apoptosis, reduced inflammation, elevated neurogenesis, and suppressed oxidative stress to reveal brain remodeling processes. Approximation of the HIE symptoms is key component in appreciating the clinical relevance of the functional deficits after injury and the recovery following transplantation [64–67]. A need for both short- and long-term characterization of safety and efficacy of stem cells will also be more clinically relevant to assess cell therapy’s immediate and prolonged effects [68]. This characterization can become a challenging issue for neonatal HIE because of endogenous spontaneous recovery in both developmental and maturation periods of the neonatal animal [69], and also seen in pediatric patients [70]. For histological evaluation, the status of the grafted cells and the host HIE needs to be assessed, using phenotypic markers of cell fate for the following: trophic factor effect, immunomodulatory response, neurogenesis, vasculogenesis, angiogenesis and synaptogenesis, as well as inflammation, tumorigenesis or ectopic tissue formation [71]. These histological assays provide insights into the modes of action of the transplanted cells, but also serve as safety measures of any adverse side effects.

Translational Study Protocols

A general rule in designing translational studies is to optimize the dose, delivery route, and timing of stem cell transplantation within clinically relevant parameters. Treating the laboratory as the clinical setting for cell therapy in HIE will enhance the translational potential of the stem cell product. Finding the minimum therapeutic cell dose may be critical and beneficial in order to avoid any potential microembolism at a high dose. Focusing on minimally invasive procedures for cell delivery will circumvent adding more trauma to the already injured brain. For timing of cell delivery, consideration should be given to the neuroprotective phase (<1 day of injury), and the neurorestorative phase (>1 day after injury) [72, 73].

Cellular and Molecular Therapeutic Pathways Underlying Stem Cell Transplantation

Cell replacement and bystander effects are the two major modes of action implicated in stem cell-mediated functional recovery in ischemic brain injury. Cellular and molecular pathways such as neurogenesis, angiogenesis, synaptogenesis, immunomodulation, and trophic factor secretion mediate neurorestorative mechanisms [32, 33, 74]. The recent use of real-time visualization techniques (i.e., magnetic resonance imaging) allows tracking of the transplants and imaging of the host neurorestorative mechanisms [75–81] originally performed in stroke and extended to HIE models [82–84].

Are We There Yet? Remaining Preclinical Issues Prior to Embarking in Cell Therapy for Neonatal Hypoxic-Ischemic Injury

Extreme caution in determining the safety and efficacy of stem cell therapy should accompany the clinical trials in neonatal hypoxic-ischemic injury. Two limited clinical trials in the US (Medical College of Georgia and Duke University) are evaluating the safety and efficacy of umbilical cord blood transplants in CP pediatric patients. Although intravenous transplantation of autologous cord blood in CP children has been found safe, long-term efficacy readouts remain to be addressed [62, 85]. Autologous bone marrow-derived MSCs have also been transplanted and found safe, but only in a single case report of CP patient ([86]). Notwithstanding, the preferred stem cells for transplantation are those derived from autologous sources. Lineage committed (neurons, glia, astrocytes) or brain region specific
cortex, hippocampus) cells have also been proposed for stem cell sources, but this cell replacement strategy has been challenged, in that convincing evidence supports the stem cell by-stander mechanism (neurotrophic, anti-inflammatory, anti-oxidative) as the primary mode of action of cell therapy, indicating non-lineage committed or non-brain region differentiated cells as equally efficacious cells for transplantation therapy. As noted above, the translation of cell therapy in neonatal ischemic-injury patients should be guided by clinically relevant animal models, utilizing a well-defined set of stem cells, tested rigorously in the laboratory and passed the safety and efficacy parameters, and at least a general understanding of the mode of action underlying the stem cells’ therapeutic benefits. In declaring that stem cell therapy has reached its prime time for clinical application, an objective measure of predictive neurologic outcomes of this novel treatment in neonatal hypoxic-ischemic injury remains elusive. Current anecdotal reports of clinical improvement following cell therapy in children with CP or HIE should not compromise the Baby STEPS’ footing on the need for solid preclinical studies to support the clinical trials. The discussion above on the Baby STEPS guidelines may be applicable to other experimental therapies for neonatal hypoxic-ischemic injury [87–90] and should be used in concert with existing pediatric stroke recommendations for research and treatment interventions [91–94].

**Combination Therapy of Cell Transplantation and Hypothermia**

All of the current brain oriented therapies, such as magnesium, calcium channel blockers and NMDA receptor antagonists, seek to interrupt the cascade triggered by HIE and thereby limits the extent of injury. To date, all therapies in human neonates who have suffered from HIE have had disappointing results in preventing the continued neuronal loss (reviewed in [95, 96]). Hypothermia, in experimental animal models of HIE, decreases glutamate release [97], attenuates secondary energy failure [23, 55, 97–99], normalizes protein synthesis [100] and attenuates free radical-induced injury [96]. Several small safety trials of hypothermia performed in human neonates [98, 99] gave promising results, while three large randomized trials of hypothermia demonstrated improvement in neurodevelopmental outcomes in neonates with mild to moderate HIE, but no improvement in neonates with severe HIE [22–24]. Recently, hypothermia has been shown to be neuroprotective by reducing the risk of neurodevelopmental disability at 18 months of age in newborns with either moderate or severe HIE [101]. Hence, while neuroprotective approaches may play a role in reducing the ongoing or escalating damage, repairing already damaged regions will still require a cellular replacement approach that may be applicable for neonates with moderate to severe HIE.

Hypothermia has been shown to afford strong neuroprotective effects against HIE pathological events, including aberrant stages of region-specific brain maturation [102], blood brain barrier (BBB) impairment [103], and mitochondrial dysfunction-induced apoptosis [104]. As highlighted above, efficacy of hypothermia is best reproduced within the first 6 hours of life for the infant with moderate to severe HIE [105–107], suggesting that hypothermia treatment protocol may benefit from a combination of therapeutic strategies [108] [109]. Several new interventions that are in clinical trial stages, including erythropoietin and helium [110–112], should also be considered for this combination therapy. More importantly, the treatment regimen for hypothermia plus these adjunctive therapies is likely to be based on the evolving pathophysiology of neonatal brain injury, as elegantly reviewed by Ferriero and colleagues [113, 114]. Combination, instead of stand-alone, therapies may be more beneficial to combat the multiple pathophysiological cell death cascades; early detection of at-risk newborns may also facilitate the prevention or the reduction in the incidence of lifelong disabilities associated with neonatal brain injury [113, 114].
As discussed above, accumulating experimental data have indicated the mobilization of bone marrow-derived stem cells, such as mesenchymal stem cells (MSCs), in brain plasticity and therapy of HIE to the affected area [115]. In the clinic, MSCs can be obtained from umbilical cord blood, adipose tissue, amniotic fluid/tissue or menstrual blood [116]. As alluded earlier, autologous MSCs may be the preferred stem cells to avoid adverse effects associated with graft rejection, but allogeneic MSCs may also be equally safe and effective due to their immature immune system, as well as their capacity to secrete anti-inflammatory factors [116]. MSCs are capable of differentiation into variety of phenotype cells [117] [110], and have been demonstrated to exert a therapeutic benefit against brain injury [105]. However, little is known regarding MSC treatment for HIE, especially in combination with hypothermia.

The observation that seizure onset beyond the first 12 hours of life is not only common in newborns with HIE [118], but also is associated with severe brain injury [50], advances the notion of a critical relationship between the onset of neonatal seizure and initiation of the therapy. Accordingly, any treatment regimen, including hypothermia, is likely to exert benefit if initiated within 6 hours after hypoxic-ischemic injury and continuing over the next 12 hours or even beyond (i.e., for 72 hours) [118]. The mechanism underlying hypothermia remains elusive, but may include its capacity to reduce oxidative stress, energy deficit, and inflammation [119]. Because of the dismal prognosis of infants with HIE, clinical enthusiasm for a novel treatment is understandable [120].

The use of delta opioid agonists may resemble certain physiological correlates of hibernation, including hypothermia [121], which may involve direct opioid receptor activation, as well as non-opioid mechanisms [122–124]. Interestingly, delta opioids may regulate neural stem and progenitor cell proliferation and differentiation [125], and may even enhance cell-based therapeutics in in vitro and in vivo disease models [126]. Our recent study [127] revealed that moderate hypothermia is efficacious in an in vitro model of hypoxic-ischemic injury, which was enhanced by MSC treatment. We also showed that the delta opioid system, along with other non-opioid neuroprotective processes, primarily contributes to the observed neuroprotection in HIE. Stem cell therapy using MSCs significantly improved the therapeutic outcome of moderate hypothermia. Primary rat neurons were exposed to oxygen-glucose deprivation (OGD) condition, a model of hypoxic-ischemic injury, then incubated at 25°C (severe hypothermia), 34°C (moderate hypothermia), and 37°C (normothermia) with or without subsequent co-culture with mesenchymal stem cells (MSCs). Combination treatment of moderate hypothermia and MSCs proved to be the optimal condition for preserving cell survival and mitochondrial activity after OGD exposure. Pharmacologic induction of hypothermia in human embryonic kidney cells (HEK293) via treatment with delta opioid peptide (DADLE) resembled moderate hypothermia’s attenuation of OGD-mediated cell alterations, which were much more pronounced in HEK293 cells overexpressing the delta opioid receptor. Further, the addition of DADLE to 34°C hypothermia and stem cell treatment in primary rat neurons showed synergistic neuroprotective effects against OGD which were significantly more robust than the dual combination of moderate hypothermia and MSCs, and were significantly reduced, but not completely abolished, by the opioid receptor antagonist naltrexone altogether implicating a ligand-receptor mechanism of neuroprotection. Investigations into other therapeutic signaling pathways revealed growth factor upregulation (i.e., GDNF) and anti-apoptotic function accompanying the observed therapeutic benefits. These results support combination therapy of hypothermia and stem cells for hypoxic-ischemic injury, which may have direct impact on current clinical trials using stand-alone hypothermia or stem cells for treating neonatal hypoxic-ischemic brain injury.
Conclusions

Stem cell therapy has emerged as an experimental treatment for neonatal hypoxic-ischemic brain injury. There is an urgent demand to introduce this therapy in the clinic for children with neonatal hypoxic-ischemic brain injury. Unfortunately, additional translational research studies are warranted in order to advance this cellular therapy from the laboratory to the clinic. The clinical entry of cell transplantation in neonatal hypoxic-ischemic brain injury will benefit from published laboratory studies and ongoing clinical trials of stem cell therapy in adult stroke. However, while neonatal hypoxic-ischemic injury shares overlapping pathologies with adult stroke, the former displays unique disease symptoms that will require a modified translational approach prior to clinical application. Consideration of combination therapy involving hypothermia and stem cell transplantation may improve the outcome of cell therapy in neonatal hypoxic-ischemic injury. The primary outcomes of this combination therapy can be measured by functional parameters such as behavioral tests and histological assays of brain status. Moreover, the use of biomarkers via neuroimaging may serve as surrogate markers of brain remodeling which allows close monitoring of the transplant recipient at different time points post-intervention over several months or even years, thereby facilitating the long-term demonstration of stable functional effects by the combination therapy.

Future perspective

Stem cell therapy for neonatal hypoxic-ischemic brain injury remains experimental. Limited clinical trials of transplantation of autologous umbilical cord blood cells for CP children are underway, but extending this therapy to other neonatal diseases will require solid preclinical safety and efficacy data for each indication. Standardized experimental models with quantitative functional endpoints and predictive clinical outcomes are an urgent need for translational research. Intermediate goals over the next five years will be optimizing the route of delivery, cell dose and timing of transplantation after diagnosis of neonatal brain injury. Target patient population for the initial clinical trials will be full term infants because of the difficulty in detecting encephalopathy in premature babies. It is envisioned that a decade from now, once more sensitive diagnostic tools (neuroimaging) and laboratory data are available, cell therapy will be tested in preterm infants with encephalopathy. The recognition that HIE or NE is associated with multiple cell death pathways will also attract research investigations on combination therapies over the next ten years. In particular, hypothermia and other neuroprotective strategies currently in clinical stage will be tested as adjunctive therapies to stem cell transplantation. Rigorous experimental testing of stem cells and combination therapies can be leveraged by adhering to relevant translational research guidelines [e.g., 128] to enhance the safe and effective clinical outcome of these interventions for treating neonatal hypoxic-ischemic brain injury.

Acknowledgments

CVB is supported by NIH NINDS 1R01NS071956-01, James and Esther King Foundation for Biomedical Research Program 1KG01-33966, SanBio Inc., Celgene Cellular Therapeutics, KMPHC and NeuralStem Inc.

Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>HI</td>
<td>Hypoxic-ischemia</td>
</tr>
<tr>
<td>HIE</td>
<td>Hypoxic-ischemic encephalopathy</td>
</tr>
<tr>
<td>NE</td>
<td>Neonatal encephalopathy</td>
</tr>
</tbody>
</table>
CP  Cerebral palsy
PVL  Periventricular Leukomalacia
STEPS  Stem cell Therapeutics as an Emerging Paradigm for Stroke
MSCs  mesenchymal stem cells

References

* References of interest
** considerable interest


Future Neurol. Author manuscript; available in PMC 2013 April 03.


Future Neurol. Author manuscript; available in PMC 2013 April 03.


Executive Summary/Executive summary headings

Neonatal Hypoxic-Ischemic Brain Injury: A Disease Target for Cell Therapy

- Neonatal hypoxia-ischemia brain injury leads to HIE, CP and PVL.
- Cell-based therapy may prove safe and effective for HIE.

Translating Stem Cells from Bench to Bedside

- The importance of implementing a baby STEPS program facilitates the translation of stem cell therapy, as stand alone or in combination with neuroprotective therapies, from the laboratory to the clinic.

Experimental Models of Neonatal Hypoxic-Ischemic Brain Injury.

- Appropriate animal models that allow predictive clinical outcomes are necessary in assessment of novel therapies for HIE.
- Unfortunately, current animal models do not faithfully mimic many of HIE pathology and symptoms.
- A standardized animal model for HIE that provides quantitative safety and efficacy endpoints is required for translational research.

Characterizing Transplantable Stem Cells.

- Creating a well defined cell line population that is not only safe but also effective with long-term and stable effects.
- The ideal transplantable stem cell is envisioned as a cell product that is readily available on clinical site, deliverable via non-invasive procedure, and well tolerated by the transplant recipient.

Safety and Efficacy Endpoints of Cell Therapy.

- Quantifiable outcome measures need be core experimental design for demonstrating safety and efficacy in both histological and behavioral parameters with good predictive clinical values.
- Because of the brain plasticity inherent in the neonates, delineating spontaneous from treatment-mediated effects should be considered.
- Endpoints should reveal acute as well as prolonged safety and efficacy of the stem cell product.

Translational Study Protocols.

- Preclinical investigations are needed to explore delivery methods of stem cells that are safe and effective via less invasive route, with clinically relevant cell dose and therapeutic window appropriate for neonates.

Cellular and Molecular Therapeutic Pathways Underlying Stem Cell Transplantation.

- Providing insights on the molecular and cellular pathways that mediate therapeutic benefits of stem cell therapy will help to optimize the treatment regimen.
- Revealing the physiological status of the transplanted cells, as well as the host brain tissue will provide additional guidance on the graft-
Are We There Yet? Remaining Preclinical Issues Prior to Embarking in Cell Therapy for Neonatal Hypoxic-Ischemic Injury

- Consideration is given to gating items that still need to be addressed in the laboratory prior to initiating clinical studies.
- Identifying optimal stem cell product should evaluate advantages and limitations of autologous and allogeneic tissue sources.

Combination Therapy of Cell Transplantation and Hypothermia

- Promising neuroprotective therapies for HIE, such as EPO and helium, with emphasis on hypothermia are discussed.
- Rationale is provided for investigating the therapeutic potential of combining stem cells and hypothermia for HIE.

Conclusion

- Stem cell therapy remains an experimental treatment for HIE.
- Rigorous translational research designed to assess safety and efficacy of stem cell therapy will pave the way for its entry to the clinic for applications in neonates.
- Combination therapy of stem cells and hypothermia for HIE may lead to improved clinical outcome.
Envisioned combination therapy of cell transplantation and neuroprotective therapies, such as hypothermia, erythropoietin (EPO) and helium for treatment of neonates with HIE or NE. These different treatment interventions as stand alone therapies can be subdivided into acute (0–48 hours after birth), subacute (6–72 hours after birth) or chronic (>72 hours after birth). Treatments targeting acute and subacute stages of neonatal brain injury correspond to neuroprotection, whereas those targeting the chronic stage represent neurorestoration. EPO or helium treatment at the acute stage, and hypothermia and stem cell therapy at the subacute stage via intravascular routes (e.g., intravenous or intra-arterial) harness neuroprotective processes, while stem cell therapy during the chronic stage via intracerebral route promotes neurorestorative mechanisms. The combination of two or more of these therapies will allow abrogation of multiple cell death pathways during the cascade of brain injury thereby arresting not one but many of the cell death signals altogether improving clinical outcome of neonates with HIE or NE.